-
InstaBlue Protein Stain Solution Protocol
2026-08-24
InstaBlue Protein Stain Solution provides rapid Coomassie-based visualization of protein bands in polyacrylamide gels without fixation, washing, or destaining. It is suited to routine protein electrophoresis analysis and MS-oriented gel workflows, but band intensity should not be treated as a validated protein quantification assay without calibration.
-
Fangchinoline Restores TFEB Lysosomal Defense Against H1N1
2026-08-24
Cheng et al. identify fangchinoline as a lysosome-targeting antiviral candidate that restores TFEB-driven lysosomal gene expression and interferes with H1N1 entry. The study combines Connectivity Map screening, transcriptomic analysis, organelle imaging, autophagy assays, time-resolved infection experiments, and in vivo validation to define a host-directed mechanism.
-
Propidium Iodide in Toxoplasma Host-Cell Assays
2026-08-23
Propidium iodide is a DNA intercalating dye that reports loss of plasma-membrane integrity, but its interpretation depends on cell identity and death mechanism. This guide translates recent GRA12 host–pathogen findings into rigorous PI-based viability, apoptosis, and necrotic cell detection strategies.
-
BHQ for Calcium Signaling Research
2026-08-22
Use BHQ to create a controlled SERCA-dependent calcium perturbation for ER stress, calcium imaging, and HSC mobilization studies. Its strongest differentiation is the ability to connect calcium-store depletion with the CaMKII-STAT3-CXCR4 axis while also supporting muscle and vascular physiology experiments.
-
Structure-Based Discovery of SARS-CoV-2 NSP15 Inhibitors
2026-08-22
The reference study used structure-based virtual screening and molecular dynamics to identify thymopentin and oleuropein as high-ranking binders of the SARS-CoV-2 NSP15 endoribonuclease. Its main contribution is a computational prioritization framework for targeting viral immune evasion, while the findings remain preliminary until biochemical, cellular, and antiviral validation is completed.
-
Annexin V-Cy5/DAPI Apoptosis Kit Workflow
2026-08-21
The Annexin V-Cy5/DAPI Apoptosis Kit provides a rapid two-parameter workflow for separating viable, early apoptotic, late apoptotic, and necrotic cells. Its flow cytometry and fluorescence microscopy compatibility makes it useful for linking treatment response to mitochondrial and signaling changes in leukemia models.
-
Baicalin Workflows for Visual Plasticity Research
2026-08-20
Baicalin offers a defined small-molecule workflow for testing adult cortical plasticity, with a reported 10 mg/kg benchmark in an amblyopia model and mechanistic readouts spanning GABAergic inhibition and perineuronal nets. Its formulation and pathway profile also support carefully separated exploratory studies in oxidative stress and cancer research.
-
Annexin V-Cy5/DAPI Apoptosis Kit Guide
2026-08-20
Learn how SKU K2255 supports rapid, two-parameter apoptosis and necrosis assessment when metabolic viability results are difficult to interpret. This scenario-driven guide covers assay principles, controls, protocol optimization, flow-cytometry interpretation, and practical vendor selection.
-
Irinotecan CPT-11: Reproducible Cell Assays
2026-08-19
Learn how Irinotecan (CPT-11, SKU A5133) can improve the interpretation and reproducibility of cell viability, proliferation, and cytotoxicity assays. This scenario-based guide covers prodrug activation, solubility, dose design, translational limits, and practical supplier selection.
-
Baicalin: From Cortical Plasticity to Assay Design
2026-08-19
Baicalin is emerging as a research tool for studying adult cortical plasticity, with evidence linking reduced GABAergic inhibition to visual recovery in mice. This article translates that finding into practical assay, formulation, and cross-domain interpretation guidance.
-
Topotecan and Dna2: Mapping Replication Stress
2026-08-18
Topotecan, also known as SKF104864, can function as more than a cytotoxic agent: it is a controllable probe of replication-fork stress and DNA-repair capacity. This article connects Topo I trapping with Dna2-dependent phenotypes to improve assay design in cancer research, glioma models, and pediatric tumor studies.
-
Drug-Sensitized Yeast for mTOR Inhibitor Discovery
2026-08-18
Breen and colleagues developed a drug-sensitized Saccharomyces cerevisiae platform that detects TOR pathway inhibitors at substantially lower concentrations than a wild-type yeast background. The system identified concentration-dependent activity for established inhibitors and aminophylline, while finding no evidence of TOR inhibition for several other compounds, including nebivolol.
-
Topotecan in First-Line Small Cell Lung Cancer
2026-08-17
This review evaluates Topotecan as an investigational first-line option for small cell lung cancer, emphasizing its distinct topoisomerase I mechanism, combination potential, and manageable noncumulative toxicity. Phase II signals were promising, but the authors appropriately identify the need for confirmatory trials before routine replacement of platinum–etoposide therapy.
-
P2RX1, Calcium Signaling, and Apoptosis in Ph+ ALL
2026-08-17
A 2025 study identifies P2RX1 as a regulator of tyrosine kinase inhibitor sensitivity in Philadelphia chromosome-positive acute lymphoblastic leukemia, linking excessive purinergic signaling to calcium/CaMKII activation, PI3K/Akt suppression, mitochondrial dysfunction, and intrinsic apoptosis. Its findings provide a mechanistic framework for interpreting drug-induced cell death while highlighting the need for orthogonal apoptosis and mitochondrial assays.
-
Camptothecin Workflows for DNA Damage Research
2026-08-16
Camptothecin is a mechanistically defined topoisomerase I inhibitor for connecting DNA lesions with cell fate, autophagy, and adaptive evolution. This workflow shows how to optimize exposure, separate acute damage from long-term selection, and translate prion-driven mutagenesis findings into practical cancer-biology assays.